Streptococcus agalactiae, a frequent but not so well-known cause of bone and joint infections: a Multicentric observational study 2014-23

This multicentric observational study of 1,454 adults with bone and joint infections reveals that *Streptococcus agalactiae* is the predominant streptococcal species involved, accounting for 29% of cases and being specifically associated with risk factors such as arteriopathy, obesity, and diabetes, as well as a higher prevalence of chronic lower-limb and diabetic foot infections.

The Gist

Imagine your body is a bustling city. Usually, the most common troublemakers causing damage to the city's infrastructure (your bones and joints) are the "Staph" gang—familiar, aggressive, and well-known criminals. But there's a second gang, the "Streptococcus" crew, that is also causing trouble, just not as loudly.

This research paper is like a detective report from a ten-year investigation into a specific, often overlooked member of that second gang: Streptococcus agalactiae (often called Group B Strep). While doctors know this bacteria can cause infections, they haven't really studied how it behaves in bone and joint infections compared to its cousins.

Here is the story of what they found, explained simply:

The Investigation

The researchers acted like detectives, looking back at the files of 1,454 patients across six major hospitals in western France between 2014 and 2023. They focused only on cases where the bacteria was positively identified in the bone or joint.

The Big Reveal:
Out of all the Streptococcus infections they found, S. agalactiae was the leader, accounting for nearly 30% of the cases. It's not a rare villain; it's a major player.

The Profile of the Villain

The study tried to figure out: Who gets infected by this specific bacteria, and how does it attack?

1. The "Target Audience":
   This bacteria doesn't just attack random people. It seems to have a specific "type." It loves to target people with metabolic issues.

   • The "Heavy Load" Analogy: Think of the body as a truck. If the truck is overloaded (Obesity) or has a broken engine (Diabetes), or if the roads it travels on are cracked and narrow (Arteriopathy/blood vessel disease), this bacteria is more likely to break in.
   • The study found that obesity and blood vessel disease were the strongest independent risk factors. If you have these, your risk of getting infected by this specific bacteria goes up significantly.

2. The "Crime Scene":

   • Where: It mostly attacks the lower body (legs and feet).
   • What: It loves prosthetic joints (like fake knees or hips) and diabetic foot ulcers.
   • The "Slow Burn": Unlike some bacteria that strike fast and furious, this one is a slow burner. The infections were more likely to be chronic (lasting a long time) rather than sudden and acute. It's like a slow leak in a pipe rather than a burst pipe.

3. The "Gang Up":
   This bacteria rarely works alone. About half the time, it shows up with other bad guys (like Staph aureus or gut bacteria). It's a team player in crime, making the infection harder to treat because you have to fight multiple enemies at once.

The Treatment Puzzle

For a long time, doctors thought, "Oh, this is just Streptococcus. It's easy to kill with penicillin, so the patient will be fine."

• The Twist: The study suggests this is a dangerous assumption. Because these infections are often chronic, involve prosthetic devices, and are mixed with other bacteria, they are harder to cure than previously thought.
• Resistance: While the bacteria is still sensitive to penicillin (the main weapon), it is getting better at resisting other common antibiotics like erythromycin and clindamycin. It's learning to dodge the backup weapons.

The Takeaway

Think of S. agalactiae not as a minor nuisance, but as a specialized, stealthy intruder.

• Who to watch out for: Patients with obesity, diabetes, or poor circulation.
• What to expect: Infections that linger in the legs or feet, often involving fake joints, and usually involving a mix of bacteria.
• The lesson: Doctors need to stop treating these infections as "easy wins." They require a more complex, multi-pronged approach because the bacteria is hiding in a body that is already struggling with other health issues.

In short: This paper wakes us up to the fact that this specific bacteria is a major cause of difficult bone infections, especially in people with metabolic health challenges, and it needs to be treated with more respect and caution than before.

Technical Summary

1. Problem Statement

Bone and joint infections (BJIs) are complex conditions with significant morbidity and mortality. While Staphylococcus is the primary pathogen, the Streptococcus genus is the second most common cause, with Streptococcus agalactiae (Group B Streptococcus) being the predominant species within this genus.

Despite its prevalence, clinical and prognostic data regarding S. agalactiae BJIs remain scarce compared to Staphylococcus. Existing literature suffers from:

• A lack of direct comparative studies against other streptococcal species.
• Inconsistent reporting of risk factors (e.g., diabetes prevalence ranges from <20% to >50% in different cohorts).
• Uncertainty regarding whether comorbidities are specific drivers of S. agalactiae invasion or merely characteristics of the aging, comorbid population undergoing arthroplasty.
• Contradictory data on treatment outcomes; while historically considered responsive to conservative management, recent studies suggest high failure rates (up to 42%) for prosthetic joint infections (PJIs) managed with debridement, antibiotics, and implant retention (DAIR).

2. Methodology

Study Design:

• Type: Retrospective observational cohort study.
• Data Source: The West Region cohort of the CRIOAc registry (French national network for complex BJIs), encompassing six university hospitals.
• Period: January 1, 2014 – December 31, 2023.
• Population: Adults (>18 years) with microbiologically confirmed streptococcal BJIs. Inclusion required compatible clinical/radiological presentation and positive microbiological samples (blood, joint fluid, or surgical tissue) validated by multidisciplinary meetings (MM).
• Sample Size: 1,454 patients (after exclusions) out of 1,8099 evaluated. Of these, 423 (29%) had S. agalactiae and 1,031 had other streptococcal species.

Data Collection & Definitions:

• Data included demographics, medical history, clinical diagnosis, microbiology, and therapeutic interventions.
• Definitions:
  • Chronic infection: Lasting >4 weeks.
  • Obesity: BMI >30 kg/m².
  • Chronic kidney failure: eGFR <30 mL/min/1.73m².
  • Device-related infection: Classified as Early (<1 mo), Delayed (1–12 mo), or Late (>12 mo).
• Quality Control: Data from 29% of the cohort (420/1454) were cross-verified with electronic patient records, showing >99.5% concordance.

Statistical Analysis:

• Software: R (v4.5.1) and GraphPad Prism.
• Comparisons: Student's t-test/Mann-Whitney for continuous variables; Chi-square/Fisher's exact for categorical variables.
• Adjustments: P-values were adjusted using the Benjamini-Hochberg procedure to control the false discovery rate.
• Multivariate Analysis: Logistic regression was used to identify independent risk factors for S. agalactiae BJIs. Variables with univariate p < 0.2 were included. Model selection was based on the Akaike Information Criterion (AIC).
• Sensitivity Analysis: Performed by excluding diabetic foot osteitis cases to isolate the effect of comorbidities.

3. Key Contributions

• First Large-Scale Comparative Analysis: This study provides one of the largest cohorts directly comparing S. agalactiae BJIs against other streptococcal BJIs, moving beyond isolated case series.
• Identification of Specific Risk Profiles: It isolates specific metabolic and vascular risk factors (arteriopathy and obesity) that are independently associated with S. agalactiae, distinguishing them from general streptococcal infections.
• Microbiological Surveillance: It documents emerging resistance patterns, specifically high rates of tetracycline resistance (~80%) and unexpectedly high erythromycin resistance (44%) in S. agalactiae isolates within this specific cohort.
• Clinical Phenotyping: It characterizes S. agalactiae BJIs as distinctively more chronic, lower-limb localized, and frequently polymicrobial (specifically with Gram-negative bacilli) compared to other streptococcal infections.

4. Key Results

Demographics & Comorbidities:

• Cohort: Median age 67 years; 65% male.
• Prevalence: S. agalactiae accounted for 29% (423/1454) of streptococcal BJIs.
• Risk Factors:
  • Obesity: 30% in S. agalactiae vs. 24% in others (univariate p=0.17).
  • Diabetes: 31% in S. agalactiae vs. 21% in others (univariate p=0.03).
  • Arteriopathy: 11% in S. agalactiae vs. 5% in others (univariate p=0.03).

Clinical Presentation:

• Location: S. agalactiae infections were significantly more likely to be lower-limb infections (57% vs. 49%, p=0.04) and chronic (p=0.04).
• Diabetic Foot: Significantly more associated with S. agalactiae (11% vs. 7%, p=0.05).
• Polymicrobial Infection: 56% of S. agalactiae cases were polymicrobial vs. 48% of others (p=0.1). Among co-pathogens, Gram-negative bacilli were significantly more frequent with S. agalactiae (49% vs. 40%, p=0.04).
• Systemic Spread: S. agalactiae was associated with less bacteremia and infective endocarditis compared to other streptococci (1.7% vs. 5.1%, p=0.04).

Multivariate Analysis (Independent Risk Factors):
After adjusting for confounders, the following were independently associated with S. agalactiae BJIs:

1. Arteriopathy: OR 4.16 (95% CI: 1.64–11.24; p=0.003).
2. Obesity: OR 2.57 (95% CI: 1.41–4.78; p=0.002).

• Note: Diabetes mellitus was not an independent risk factor in the multivariate model (OR 1.40, p=0.287), likely due to confounding by the high prevalence of diabetic foot osteitis in this group.

Microbiology:

• Antibiotic Susceptibility: 100% penicillin susceptibility for S. agalactiae.
• Resistance: High tetracycline resistance (~80%). Erythromycin resistance was 44% (higher than national surveillance data of 29–34%). Clindamycin resistance is increasing.

5. Significance and Conclusion

This study establishes S. agalactiae as a distinct and prominent pathogen in complex bone and joint infections, characterized by a specific clinical phenotype:

• Patient Profile: Older adults with specific metabolic and vascular comorbidities (obesity and arteriopathy).
• Infection Characteristics: More likely to be chronic, located in the lower limb, and polymicrobial (often with Gram-negative bacilli).
• Clinical Implications:
  • Clinicians should maintain a high index of suspicion for S. agalactiae in patients with obese/vascular comorbidities presenting with chronic lower-limb infections.
  • The high rate of macrolide/lincosamide resistance suggests that empirical therapy should be guided by local antibiograms rather than assuming susceptibility.
  • The chronic nature and polymicrobial profile may explain the high treatment failure rates observed in recent literature, necessitating aggressive surgical management and prolonged antibiotic courses.

Limitations: Retrospective design, potential underreporting of certain comorbidities (e.g., hypertension), lack of long-term outcome data (recurrence, functional recovery), and restriction to complex cases managed in a specialized network (potentially excluding mild native infections).

Future Directions: The authors call for prospective studies to better understand the prognostic factors and optimize management strategies, particularly for polymicrobial and device-associated infections.